Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 2/20 | 0.37 |
| ▸ | CSF1R | P07333 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | INSR | P06213 | 2/20 | 0.34 |
| ▸ | IGF1R | P08069 | 2/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | ACP1 | P24666 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29936464 | 1.00 | PARP14 (0.37) | PARP14CSF1RMAPK1MAPTPKM | |
| SCHEMBL3001964 | 0.92 | GAA (0.35) | MAPK1MAPTPKMRAB9AHTR2A | |
| SCHEMBL31043041 | 0.91 | CSF1R (0.44) | PARP14CSF1RMAPK1MAPTPKM | |
| SCHEMBL3009574 | 0.91 | CSF1R (0.44) | PARP14CSF1RMAPK1MAPTPKM | |
| SCHEMBL13632454 | 0.90 | CSF1R (0.39) | PARP14CSF1RMAPK1MAPTPKM | |
| SCHEMBL3008125 | 0.88 | CSF1R (0.38) | PARP14CSF1RMAPTHTR2AKDM4E | |
| SCHEMBL27800990 | 0.85 | CSF1R (0.34) | PARP14CSF1RMAPK1INSRIGF1R | |
| SCHEMBL2995845 | 0.83 | PARP14 (0.39) | PARP14CSF1RMAPK1MAPTPKM | |
| SCHEMBL3006361 | 0.82 | JAK1 (0.38) | PARP14CSF1RMAPK1MAPTPKM | |
| SCHEMBL1897623 | 0.81 | CSF1R (0.42) | PARP14CSF1RMAPK1MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213583-A1 | ANTIVIRAL PHARMACEUTICAL COMPOSITION AND USE THEREOF | MITOIMMUNE THERAPEUTICS INC. (KR) | 2025-07-03 | — | — | US | claimed |
| US-20250082646-A1 | OVARIAN ANTI-AGING PHARMACEUTICAL COMPOSITION AND USE THEREOF | MITOIMMUNE THERAPEUTICS INC. (KR) | 2025-03-13 | — | — | US | claimed |
| EP-4470541-A1 | OVARIAN ANTI-AGING PHARMACEUTICAL COMPOSITION AND USE THEREOF | MitoImmune Therapeutics Inc. (KR) | 2024-12-04 | — | — | EP | claimed |
| US-20240374646-A1 | COMPOSITION FOR INHIBITING INFLAMMATION OR AGING OF STEM CELLS, AND METHOD FOR INHIBITING INFLAMMATION OR AGING BY USING SAME | MITOIMMUNE THERAPEUTICS INC. (KR) | 2024-11-14 | — | — | US | claimed |
| US-20240269145-A1 | USE OF INDOLE COMPOUND AS INHIBITORS OF FERROPTOSIS | MITOIMMUNE THERAPEUTICS INC. (KR) | 2024-08-15 | — | — | US | claimed |
| EP-4382106-A1 | COMPOSITION FOR INHIBITING INFLAMMATION OR AGING OF STEM CELLS, AND METHOD FOR INHIBITING INFLAMMATION OR AGING BY USING SAME | MitoImmune Therapeutics Inc. (KR) | 2024-06-12 | — | — | EP | claimed |
| WO-2023182840-A1 | ANTIVIRAL PHARMACEUTICAL COMPOSITION AND USE THEREOF | 주식회사 미토이뮨테라퓨틱스 | 2023-09-28 | — | — | WO | claimed |
| WO-2023146341-A1 | OVARIAN ANTI-AGING PHARMACEUTICAL COMPOSITION AND USE THEREOF | 주식회사 미토이뮨테라퓨틱스 | 2023-08-03 | — | — | WO | claimed |
| EP-2178870-B1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG CHEMICAL LTD (KR) | 2018-09-19 | — | — | EP | claimed |
| US-20150038500-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING OPHTHALMIC DISORDERS | CATHOLIC UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2015-02-05 | — | — | US | claimed |
| EP-2230238-B1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG LIFE SCIENCES LTD (KR) | 2013-12-11 | — | — | EP | claimed |
| US-8436038-B2 | Indole and indazole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2013-05-07 | — | — | US | claimed |
| US-8349885-B2 | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect | LG LIFE SCIENCES LTD. (KR) | 2013-01-08 | — | — | US | claimed |
| US-20120270203-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG CHEM, LTD. (KR) | 2012-10-25 | — | — | US | claimed |
| US-20100291533-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG LIFE SCIENCES LTD. (KR) | 2010-11-18 | — | — | US | claimed |
| EP-2230238-A2 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG Life Sciences Ltd. (KR) | 2010-09-22 | — | — | EP | claimed |
| US-20100197673-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD (KR) | 2010-08-05 | — | — | US | claimed |
| EP-2178870-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG Life Sciences Ltd. (KR) | 2010-04-28 | — | — | EP | claimed |
| WO-2009025478-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2009-02-26 | — | — | WO | claimed |
| EP-4470541-A1 | OVARIAN ANTI-AGING PHARMACEUTICAL COMPOSITION AND USE THEREOF | MitoImmune Therapeutics Inc. (KR) | 2024-12-04 | — | — | EP | disclosed |
| EP-4382106-A1 | COMPOSITION FOR INHIBITING INFLAMMATION OR AGING OF STEM CELLS, AND METHOD FOR INHIBITING INFLAMMATION OR AGING BY USING SAME | MitoImmune Therapeutics Inc. (KR) | 2024-06-12 | — | — | EP | disclosed |
| EP-2178870-B1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG CHEMICAL LTD (KR) | 2018-09-19 | — | — | EP | disclosed |
| US-9000028-B2 | Indole and indazole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2015-04-07 | — | — | US | disclosed |
| US-20150038500-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING OPHTHALMIC DISORDERS | CATHOLIC UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2015-02-05 | — | — | US | disclosed |
| EP-2230238-B1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG LIFE SCIENCES LTD (KR) | 2013-12-11 | — | — | EP | disclosed |
| US-20130237532-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2013-09-12 | — | — | US | disclosed |
| US-8436038-B2 | Indole and indazole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2013-05-07 | — | — | US | disclosed |
| US-8349885-B2 | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect | LG LIFE SCIENCES LTD. (KR) | 2013-01-08 | — | — | US | disclosed |
| US-8349885-B2 | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect | LG LIFE SCIENCES LTD. (KR) | 2013-01-08 | — | — | US | disclosed |
| US-8349885-B2 | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect | LG LIFE SCIENCES LTD. (KR) | 2013-01-08 | — | — | US | disclosed |
| US-20120270203-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG CHEM, LTD. (KR) | 2012-10-25 | — | — | US | disclosed |
| US-20120270203-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG CHEM, LTD. (KR) | 2012-10-25 | — | — | US | disclosed |
| US-20120270203-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG CHEM, LTD. (KR) | 2012-10-25 | — | — | US | disclosed |
| US-20100291533-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG LIFE SCIENCES LTD. (KR) | 2010-11-18 | — | — | US | disclosed |
| US-20100291533-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG LIFE SCIENCES LTD. (KR) | 2010-11-18 | — | — | US | disclosed |
| US-20100291533-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG LIFE SCIENCES LTD. (KR) | 2010-11-18 | — | — | US | disclosed |
| EP-2230238-A2 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG Life Sciences Ltd. (KR) | 2010-09-22 | — | — | EP | disclosed |
| EP-2230238-A2 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG Life Sciences Ltd. (KR) | 2010-09-22 | — | — | EP | disclosed |
| US-20100197673-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD (KR) | 2010-08-05 | — | — | US | disclosed |
| US-20100197673-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD (KR) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374646-A1 | COMPOSITION FOR INHIBITING INFLAMMATION OR AGING OF STEM CELLS, AND METHOD FOR INHIBITING INFLAMMATION OR AGING BY USING SAME | TFAM, FIS1, AIFM1 | PARP14 4300/4885CSF1R 1534/4885MAPK1 116/4885 |
| US-20250082646-A1 | OVARIAN ANTI-AGING PHARMACEUTICAL COMPOSITION AND USE THEREOF | CYP19A1, NR5A1, CYP11A1 | PARP14 2752/4885CSF1R 4503/4885MAPK1 151/4885 |
| US-20250213583-A1 | ANTIVIRAL PHARMACEUTICAL COMPOSITION AND USE THEREOF | ZC3HAV1, ZC3HAV1L, SARS1 | PARP14 4358/4885CSF1R 3618/4885MAPK1 414/4885 |
| US-20120270203-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | IDO1, IDO2, INMT | PARP14 3292/4885CSF1R 2444/4885MAPK1 1391/4885 |
| US-20130237532-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | IDO1, IDO2, NFATC1 | PARP14 2120/4885CSF1R 2910/4885MAPK1 1650/4885 |
| US-20100197673-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | IDO1, IDO2, NFATC1 | PARP14 2120/4885CSF1R 2910/4885MAPK1 1650/4885 |
| US-20150038500-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING OPHTHALMIC DISORDERS | AQP1, EYA3, SF1 | PARP14 4817/4885CSF1R 3822/4885MAPK1 634/4885 |
| US-20100291533-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | IDO1, IDO2, INMT | PARP14 3292/4885CSF1R 2444/4885MAPK1 1391/4885 |
| US-20240269145-A1 | USE OF INDOLE COMPOUND AS INHIBITORS OF FERROPTOSIS | AIFM2, FECH, SLC40A1 | PARP14 4221/4885CSF1R 1524/4885MAPK1 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.